Ocugen Cuts Borrowing Costs by Nearly Half After $130M Convertible, as OCU410 Data Shows 31% Lesion Reduction

Ocugen refinances $130M debt to 6.75% but stock drops 26% on dilution fears. Phase 2 data for OCU410 shows 31% lesion reduction, double current therapies. Pivotal Phase 3 planned for 2026.

Ocugen has used a fresh $130 million convertible note issuance to refinance expensive debt, slashing its annual interest burden from 12.5% to just 6.75%. The biotech group fully repaid a loan from Avenue Capital Group with part of the proceeds, leaving it with net proceeds of roughly $112 million — enough to fund operations into 2028. Yet the stock has failed to catch a bid, sliding around 26% over the past month on concerns that the convertible will dilute existing shareholders. Shares closed the week at €1.18 on German exchanges.

The market’s pessimism stands in stark contrast to the company’s clinical progress. Ocugen unveiled fresh data from a Phase 2 trial of OCU410, its gene therapy candidate for geographic atrophy, at the Retina World Congress in Florida. After 12 months, patients receiving a mid-range dose showed a 31% reduction in lesion growth compared with the control arm. That treatment effect is roughly double what has been reported for currently approved therapies, underscoring the potential of the company’s modifier gene therapy platform.

Around 266 million people worldwide suffer from dry age-related macular degeneration, the advanced form of which is geographic atrophy. The commercial opportunity is enormous, and Ocugen is positioning OCU410 as a potential first?in?class option. The company plans to kick off a pivotal Phase 3 trial for the asset in the third quarter of 2026, enrolling 300 patients across the U.S. and Europe. The study will use an adaptive design targeting statistical power of over 95%.

Ocugen is also advancing its lead candidate OCU400 for retinitis pigmentosa. A rolling biologics license application is expected to be submitted in the same period. The back?half of 2026 therefore shapes up as a critical window for the pipeline, with two major milestones on the horizon.

On the financial side, the first quarter offered a mixed picture. Revenue came in at $1.53 million, beating analyst estimates, while the loss per share of $0.06 came in slightly deeper than expected. The convertible refinancing has removed a near?term liquidity overhang, but the overhang for equity holders has not lifted.

A number of Street analysts remain constructive despite the stock’s slide. H.C. Wainwright and Oppenheimer both reiterated buy ratings recently, with one analyst sticking to a $12 price target and citing the compelling gene therapy data. The management team will have another chance to pitch the story to institutional investors on May 26 at the Stifel Ophthalmology Forum.

Technically, the stock now screens as deeply oversold. The relative strength index sits at 25, while the shares trade nearly 25% below their 50?day moving average of $1.57. For investors willing to look past the near?term dilution fears, the next few months could offer catalysts capable of turning sentiment around.